Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 2.65 thousand shares for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-03-31
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2014-06-30 was 14.75K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2014-03-31 was 4.50K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2013-12-31 was 0.00 shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2012-12-31 was -2.60K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 2.65K shares, a 88.02% decline from fiscal 2023.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 22.10K shares, a 68.27% decline from fiscal 2022.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 69.65K shares, a 4657.51% increase from fiscal 2021.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2021 was 1.46K shares, a 94.91% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | 2.65K shares 10-K · filed 2026-03-31 | 39.70K shares 10-K · filed 2025-02-27 | |||
| 2023-12-31 | 22.10K shares 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | 69.65K shares 10-K · filed 2024-03-28 | ||||
| 2021-12-31 | 1.46K shares 10-K · filed 2023-03-30 | 1.47K shares 10-K · filed 2022-03-31 | |||
| 2020-12-31 | 28.77K shares 10-K · filed 2022-03-31 | 431.61K shares 10-K · filed 2021-03-19 | |||
| 2019-12-31 | 29.25K shares 10-K · filed 2021-03-19 | ||||
| 2016-12-31 | 112.00K shares 10-K · filed 2017-03-24 | ||||
| 2015-12-31 | 88.50K shares 10-K · filed 2017-03-24 | ||||
| 2014-12-31 | 26.25K shares 10-K · filed 2016-03-30 | ||||
| 2014-06-30 | 14.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | 19.25K shares 10-Q · filed 2014-08-07 | 19.25K shares derived: sum of 3 quarters · filed 2016-03-30 | ||
| 2014-03-31 | 4.50K shares 10-Q · filed 2014-05-08 | 4.50K shares derived: sum of 2 quarters · filed 2016-03-30 | |||
| 2013-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | 111.00 shares 10-K · filed 2016-03-30 | |||
| 2013-09-30 | 111.00 shares 10-Q · filed 2013-11-12 | ||||
| 2012-12-31 | -2.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | 1.44K shares derived: sum of 2 quarters · filed 2015-03-12 | 2.94K shares 10-K · filed 2015-03-12 | 13.24K shares 10-K · filed 2013-03-18 | |
| 2012-09-30 | 4.04K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | 5.54K shares 10-Q · filed 2012-11-09 | |||
| 2012-06-30 | 1.50K shares 10-Q · filed 2012-08-14 | ||||
| 2011-12-31 | 11.33K shares 10-K · filed 2014-03-13 | 51.00K shares 10-K · filed 2013-03-18 | |||
| 2010-12-31 | 113.24K shares 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |